On the public citation graph

CDK4 and CDK6 kinases: From basic science to cancer therapy

https://doi.org/10.1126/science.abc1495
0 signed · 634 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2019.4782openalex-snapshot
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
inferredcites →https://doi.org/10.1002/ijc.31220openalex-snapshot
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
inferredcites →https://doi.org/10.1007/s00109-016-1475-3openalex-snapshot
Cyclin D1, cancer progression, and opportunities in cancer treatment
inferredcites →https://doi.org/10.1007/s13402-017-0316-xopenalex-snapshot
Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss
inferredcites →https://doi.org/10.1016/0092-8674(91)90100-dopenalex-snapshot
Human D-type cyclin
inferredcites →https://doi.org/10.1016/0092-8674(91)90101-4openalex-snapshot
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
inferredcites →https://doi.org/10.1016/j.annonc.2020.08.2240openalex-snapshot
LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
inferredcites →https://doi.org/10.1016/j.ccell.2016.02.006openalex-snapshot
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
inferredcites →https://doi.org/10.1016/j.ccell.2017.11.006openalex-snapshot
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
inferredcites →https://doi.org/10.1016/j.ccell.2018.11.006openalex-snapshot
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
inferredcites →https://doi.org/10.1016/j.ccell.2020.01.007openalex-snapshot
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
inferredcites →https://doi.org/10.1016/j.ccell.2020.03.010openalex-snapshot
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
inferredcites →https://doi.org/10.1016/j.ccell.2021.08.009openalex-snapshot
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
inferredcites →https://doi.org/10.1016/j.ccr.2005.12.012openalex-snapshot
Requirement for CDK4 kinase function in breast cancer
inferredcites →https://doi.org/10.1016/j.ccr.2005.12.019openalex-snapshot
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
inferredcites →https://doi.org/10.1016/j.ccr.2010.05.025openalex-snapshot
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
inferredcites →https://doi.org/10.1016/j.ccr.2010.08.012openalex-snapshot
Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 Methyltransferase
inferredcites →https://doi.org/10.1016/j.ccr.2011.10.001openalex-snapshot
A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
inferredcites →https://doi.org/10.1016/j.ccr.2012.09.015openalex-snapshot
The Requirement for Cyclin D Function in Tumor Maintenance
inferredcites →https://doi.org/10.1016/j.ccr.2014.05.020openalex-snapshot
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
inferredcites →https://doi.org/10.1016/j.cell.2004.07.025openalex-snapshot
Mouse Development and Cell Proliferation in the Absence of D-Cyclins
inferredcites →https://doi.org/10.1016/j.cell.2004.08.002openalex-snapshot
Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6
inferredcites →https://doi.org/10.1016/j.cell.2018.09.006openalex-snapshot
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
inferredcites →https://doi.org/10.1016/j.celrep.2015.12.094openalex-snapshot
Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
inferredcites →https://doi.org/10.1016/j.celrep.2017.10.042openalex-snapshot
Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System
inferredcites →https://doi.org/10.1016/j.celrep.2018.02.053openalex-snapshot
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
inferredcites →https://doi.org/10.1016/j.celrep.2019.02.023openalex-snapshot
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
inferredcites →https://doi.org/10.1016/j.celrep.2020.03.068openalex-snapshot
Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1
inferredcites →https://doi.org/10.1016/j.ebiom.2019.03.027openalex-snapshot
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
inferredcites →https://doi.org/10.1016/j.ejmech.2017.12.003openalex-snapshot
A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy
inferredcites →https://doi.org/10.1016/j.molcel.2018.10.034openalex-snapshot
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
inferredcites →https://doi.org/10.1016/j.molcel.2019.03.020openalex-snapshot
Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix
inferredcites →https://doi.org/10.1016/j.molcel.2019.08.020openalex-snapshot
Transient Hysteresis in CDK4/6 Activity Underlies Passage of the Restriction Point in G1
inferredcites →https://doi.org/10.1016/j.redox.2017.12.017openalex-snapshot
Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair
inferredcites →https://doi.org/10.1016/s0065-230x(08)60352-8openalex-snapshot
Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer
inferredcites →https://doi.org/10.1016/s0092-8674(00)80788-6openalex-snapshot
Rescue of Cyclin D1 Deficiency by Knockin Cyclin E
inferredcites →https://doi.org/10.1016/s1470-2045(14)71159-3openalex-snapshot
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
inferredcites →https://doi.org/10.1016/s1470-2045(15)00613-0openalex-snapshot
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(18)30292-4openalex-snapshot
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
inferredcites →https://doi.org/10.1016/s1470-2045(19)30616-3openalex-snapshot
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
inferredcites →https://doi.org/10.1016/s1535-6108(03)00053-9openalex-snapshot
Proliferation of cancer cells despite CDK2 inhibition
inferredcites →https://doi.org/10.1038/350512a0openalex-snapshot
A novel cyclin encoded by a bcl1-linked candidate oncogene
inferredcites →https://doi.org/10.1038/35082500openalex-snapshot
Specific protection against breast cancers by cyclin D1 ablation
inferredcites →https://doi.org/10.1038/35106065openalex-snapshot
To cycle or not to cycle: a critical decision in cancer
inferredcites →https://doi.org/10.1038/369669a0openalex-snapshot
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
inferredcites →https://doi.org/10.1038/375503a0openalex-snapshot
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
inferredcites →https://doi.org/10.1038/nature02650openalex-snapshot
Cyclin-dependent kinases regulate the antiproliferative function of Smads
inferredcites →https://doi.org/10.1038/nature22797openalex-snapshot
The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival
inferredcites →https://doi.org/10.1038/nature23465openalex-snapshot
CDK4/6 inhibition triggers anti-tumour immunity
inferredcites →https://doi.org/10.1038/nature25015openalex-snapshot
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
inferredcites →https://doi.org/10.1038/nchembio.1212openalex-snapshot
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system
inferredcites →https://doi.org/10.1038/ncomms15916openalex-snapshot
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
inferredcites →https://doi.org/10.1038/ncomms6906openalex-snapshot
Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells
inferredcites →https://doi.org/10.1038/nm.3954openalex-snapshot
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
inferredcites →https://doi.org/10.1038/nrc.2016.138openalex-snapshot
Cell cycle proteins as promising targets in cancer therapy
inferredcites →https://doi.org/10.1038/nrc2399openalex-snapshot
Cellular mechanisms of tumour suppression by the retinoblastoma gene
inferredcites →https://doi.org/10.1038/nrm.2016.27openalex-snapshot
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
inferredcites →https://doi.org/10.1038/onc.2010.154openalex-snapshot
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
inferredcites →https://doi.org/10.1038/onc.2016.379openalex-snapshot
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
inferredcites →https://doi.org/10.1038/onc.2017.120openalex-snapshot
Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer
inferredcites →https://doi.org/10.1038/s41388-018-0332-yopenalex-snapshot
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
inferredcites →https://doi.org/10.1038/s41388-018-0650-0openalex-snapshot
Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
inferredcites →https://doi.org/10.1038/s41388-019-0708-7openalex-snapshot
Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer
inferredcites →https://doi.org/10.1038/s41388-020-01532-4openalex-snapshot
Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3
inferredcites →https://doi.org/10.1038/s41467-019-09068-2openalex-snapshot
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
inferredcites →https://doi.org/10.1038/s41523-018-0097-zopenalex-snapshot
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
inferredcites →https://doi.org/10.1038/s41586-021-03422-5openalex-snapshot
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity
inferredcites →https://doi.org/10.1038/s41586-021-03445-yopenalex-snapshot
CRL4AMBRA1 is a master regulator of D-type cyclins
inferredcites →https://doi.org/10.1038/s41586-021-03474-7openalex-snapshot
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D
inferredcites →https://doi.org/10.1038/sj.onc.1205025openalex-snapshot
Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E
inferredcites →https://doi.org/10.1056/nejmoa1505270openalex-snapshot
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1607303openalex-snapshot
Palbociclib and Letrozole in Advanced Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1609709openalex-snapshot
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1810527openalex-snapshot
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1903765openalex-snapshot
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
inferredcites →https://doi.org/10.1056/nejmoa1911149openalex-snapshot
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
inferredcites →https://doi.org/10.1073/pnas.1001613107openalex-snapshot
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
inferredcites →https://doi.org/10.1073/pnas.1711477115openalex-snapshot
Kinase-independent function of E-type cyclins in liver cancer
inferredcites →https://doi.org/10.1073/pnas.1901323116openalex-snapshot
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
inferredcites →https://doi.org/10.1073/pnas.92.14.6289openalex-snapshot
Growth suppression by p16ink4 requires functional retinoblastoma protein.
inferredcites →https://doi.org/10.1073/pnas.95.3.1091openalex-snapshot
Assembly of cyclin D-dependent kinase and titration of p27 Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)
inferredcites →https://doi.org/10.1074/jbc.271.34.20608openalex-snapshot
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
inferredcites →https://doi.org/10.1074/jbc.273.45.29864openalex-snapshot
Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway
inferredcites →https://doi.org/10.1074/jbc.m112.365494openalex-snapshot
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
inferredcites →https://doi.org/10.1083/jcb.201911036openalex-snapshot
CDK4/6 regulate lysosome biogenesis through TFEB/TFE3
inferredcites →https://doi.org/10.1093/annonc/mdx784openalex-snapshot
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
inferredcites →https://doi.org/10.1093/annonc/mdz278openalex-snapshot
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
inferredcites →https://doi.org/10.1093/emboj/18.6.1571openalex-snapshot
The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts
inferredcites →https://doi.org/10.1093/neuonc/nos114openalex-snapshot
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
inferredcites →https://doi.org/10.1101/gad.12.22.3499openalex-snapshot
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
inferredcites →https://doi.org/10.1101/gad.13.12.1501openalex-snapshot
CDK inhibitors: positive and negative regulators of G1-phase progression
inferredcites →https://doi.org/10.1101/gad.854900openalex-snapshot
Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1–dependent cellular transformation
inferredcites →https://doi.org/10.1111/cas.13957openalex-snapshot
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
inferredcites →https://doi.org/10.1124/dmd.114.062745openalex-snapshot
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
inferredcites →https://doi.org/10.1126/sciadv.aax6352openalex-snapshot
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
inferredcites →https://doi.org/10.1126/sciadv.abb2210openalex-snapshot
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition
inferredcites →https://doi.org/10.1126/science.aaw2106openalex-snapshot
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
inferredcites →https://doi.org/10.1126/scitranslmed.aal3986openalex-snapshot
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
inferredcites →https://doi.org/10.1126/scitranslmed.aav7171openalex-snapshot
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
inferredcites →https://doi.org/10.1128/mcb.00898-08openalex-snapshot
p27 Kip1 Inhibits Cyclin D-Cyclin-Dependent Kinase 4 by Two Independent Modes
inferredcites →https://doi.org/10.1128/mcb.01206-14openalex-snapshot
Brk/Protein Tyrosine Kinase 6 Phosphorylates p27 KIP1 , Regulating the Activity of Cyclin D–Cyclin-Dependent Kinase 4
inferredcites →https://doi.org/10.1128/mcb.02171-06openalex-snapshot
Differential Modification of p27 Kip1 Controls Its Cyclin D-cdk4 Inhibitory Activity
inferredcites →https://doi.org/10.1128/mcb.06570-11openalex-snapshot
Genetic Reevaluation of the Role of F-Box Proteins in Cyclin D1 Degradation
inferredcites →https://doi.org/10.1128/mcb.11.10.4846openalex-snapshot
Characterization of a candidate bcl-1 gene.
inferredcites →https://doi.org/10.1128/mcb.11.10.4846-4853.1991openalex-snapshot
Characterization of a Candidate bcl-1 Gene
inferredcites →https://doi.org/10.1128/mcb.15.5.2600openalex-snapshot
Cyclin D1 Is Dispensable for G 1 Control in Retinoblastoma Gene-Deficient Cells Independently of cdk4 Activity
inferredcites →https://doi.org/10.1128/mcb.16.12.6917openalex-snapshot
Convergence of Mitogenic Signalling Cascades from Diverse Classes of Receptors at the Cyclin D–Cyclin-Dependent Kinase–pRb-Controlled G1 Checkpoint
inferredcites →https://doi.org/10.1158/0008-5472.can-05-2639openalex-snapshot
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
inferredcites →https://doi.org/10.1158/0008-5472.can-09-4559openalex-snapshot
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
inferredcites →https://doi.org/10.1158/0008-5472.can-15-0728openalex-snapshot
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-15-2931openalex-snapshot
Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
inferredcites →https://doi.org/10.1158/0008-5472.can-16-2653openalex-snapshot
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-17-2210openalex-snapshot
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-19-0708openalex-snapshot
CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
inferredcites →https://doi.org/10.1158/0008-5472.can-20-0106openalex-snapshot
Obesity/Type 2 Diabetes-Associated Liver Tumors Are Sensitive to Cyclin D1 Deficiency
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-1675openalex-snapshot
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-2955openalex-snapshot
CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-15-2869openalex-snapshot
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-1114openalex-snapshot
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-17-0754openalex-snapshot
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-0410openalex-snapshot
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-0685openalex-snapshot
CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-0475openalex-snapshot
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-0751openalex-snapshot
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
inferredcites →https://doi.org/10.1158/1535-7163.1427.3.11openalex-snapshot
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
inferredcites →https://doi.org/10.1158/1535-7163.mct-05-0383openalex-snapshot
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells
inferredcites →https://doi.org/10.1158/1535-7163.mct-14-0257openalex-snapshot
The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
inferredcites →https://doi.org/10.1158/1535-7163.mct-15-0775openalex-snapshot
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
inferredcites →https://doi.org/10.1158/1538-7445.am2019-4425openalex-snapshot
Abstract 4425: FCN-437: A novel, potent and selective oral inhibitor of CDK4/6 for the treatment of solid tumors
inferredcites →https://doi.org/10.1158/1538-7445.am2021-1279openalex-snapshot
Abstract 1279: Development of a selective CDK2-E inhibitor in CCNE driven cancers
inferredcites →https://doi.org/10.1158/1538-7445.sabcs20-pd1-06openalex-snapshot
Abstract PD1-06: Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial
inferredcites →https://doi.org/10.1158/1538-7445.sabcs20-sp12openalex-snapshot
Abstract SP012: Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors
inferredcites →https://doi.org/10.1158/1541-7786.mcr-18-0188openalex-snapshot
Tyrosine Phosphorylation of p27Kip1 Correlates with Palbociclib Responsiveness in Breast Cancer Tumor Cells Grown in Explant Culture
inferredcites →https://doi.org/10.1158/2159-8290.cd-14-0625openalex-snapshot
PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers
inferredcites →https://doi.org/10.1158/2159-8290.cd-17-0699openalex-snapshot
In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
inferredcites →https://doi.org/10.1158/2159-8290.cd-17-0745openalex-snapshot
A Preexisting Rare PIK3CA E545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
inferredcites →https://doi.org/10.1158/2159-8290.cd-17-0912openalex-snapshot
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
inferredcites →https://doi.org/10.1158/2159-8290.cd-17-0915openalex-snapshot
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
inferredcites →https://doi.org/10.1158/2159-8290.cd-18-0264openalex-snapshot
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
inferredcites →https://doi.org/10.1158/2159-8290.cd-18-0830openalex-snapshot
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
inferredcites →https://doi.org/10.1158/2159-8290.cd-19-1390openalex-snapshot
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer
inferredcites →https://doi.org/10.1172/jci41402openalex-snapshot
Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition
inferredcites →https://doi.org/10.1177/1758835918786451openalex-snapshot
CDK4/6 inhibition in breast cancer: current practice and future directions
inferredcites →https://doi.org/10.1182/blood-2007-02-071266openalex-snapshot
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
inferredcites →https://doi.org/10.1182/blood-2015-11-683581openalex-snapshot
Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
inferredcites →https://doi.org/10.1186/bcr2419openalex-snapshot
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
inferredcites →https://doi.org/10.1200/jco.18.00925openalex-snapshot
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
inferredcites →https://doi.org/10.1200/jco.20.02514openalex-snapshot
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
inferredcites →https://doi.org/10.1200/jco.2005.05.064openalex-snapshot
Cyclin D1 in Breast Cancer Pathogenesis
inferredcites →https://doi.org/10.1200/jco.2017.73.7585openalex-snapshot
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
inferredcites →https://doi.org/10.1200/jco.2017.75.6155openalex-snapshot
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2018.78.9909openalex-snapshot
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
inferredcites →https://doi.org/10.1242/jcs.039131openalex-snapshot
Transcriptional regulation of the cyclin D1 gene at a glance
inferredcites →https://doi.org/10.15252/emmm.201607012openalex-snapshot
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
inferredcites →https://doi.org/10.15252/emmm.201607084openalex-snapshot
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
inferredcites →https://doi.org/10.18632/aging.100988openalex-snapshot
FOXM1 regulates proliferation, senescence and oxidative stress in keratinocytes and cancer cells
inferredcites →https://doi.org/10.18632/oncotarget.17778openalex-snapshot
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
inferredcites →https://doi.org/10.18632/oncotarget.25803openalex-snapshot
Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway inKRAS-mutant non-small cell lung cancer
inferredcites →https://doi.org/10.18632/oncotarget.26215openalex-snapshot
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
inferredcites →https://doi.org/10.18632/oncotarget.3364openalex-snapshot
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
inferredcites →https://doi.org/10.20892/j.issn.2095-3941.2018.0257openalex-snapshot
Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance
inferredcites →https://doi.org/10.4161/15384101.2014.946841openalex-snapshot
The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
inferredcites →https://doi.org/10.4161/cc.21195openalex-snapshot
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
inferredcites →https://doi.org/10.4161/cc.7.7.5637openalex-snapshot
Switching cyclin D-Cdk4 kinase activity on and off
inferredcites →https://doi.org/10.7554/elife.02872openalex-snapshot
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4765196openalex-extracted
Discovery and Preclinical Evaluations of Tqb3616, a Novel Cdk4-Biased Inhibitor
inferred← citeshttps://doi.org/10.2139/ssrn.4779054openalex-extracted
Targeting Stat3 Potentiates Cdk4/6 Inhibitors Therapy in Hnscc
inferred← citeshttps://doi.org/10.1002/1878-0261.13351openalex-snapshot
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4 /6 inhibition
inferred← citeshttps://doi.org/10.1002/9781119834090.ch4openalex-snapshot
More Targets and Treatments
inferred← citeshttps://doi.org/10.1002/adfm.202508310openalex-snapshot
Antibody‐Programmable Bimetallic Nanozymes for Transcriptional Blockade Therapy in HER2/ER‐Positive Breast Cancer
inferred← citeshttps://doi.org/10.1002/adma.202413601openalex-snapshot
Sonoactivated Z‐Scheme Heterojunction for Enhanced Sonodynamic Mitophagy Inhibition and Triple Negative Breast Cancer Treatment
inferred← citeshttps://doi.org/10.1002/advs.202407349openalex-snapshot
Bilirubin Targeting WNK1 to Alleviate NLRP3‐Mediated Neuroinflammation
inferred← citeshttps://doi.org/10.1002/advs.202409588openalex-snapshot
XBP1s Mediates Cross‐resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer
inferred← citeshttps://doi.org/10.1002/advs.202410427openalex-snapshot
Biomimetic Targeted Co‐Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma
inferred← citeshttps://doi.org/10.1002/advs.202413103openalex-snapshot
Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
inferred← citeshttps://doi.org/10.1002/advs.202510501openalex-snapshot
CDK4/6 Inhibitor Priming Enhances PD‐1 Blockade via Sell hi Neutrophil‐Induced Stat5a + Progenitor Exhausted CD8 + T Cell
inferred← citeshttps://doi.org/10.1002/advs.202518978openalex-snapshot
NK Cell Activation by Platinum Boosts Immunotherapy in HR + /HER2 − Breast Cancer
inferred← citeshttps://doi.org/10.1002/advs.75693openalex-snapshot
ZDHHC17‐Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance
inferred← citeshttps://doi.org/10.1002/bcp.70265openalex-snapshot
Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
inferred← citeshttps://doi.org/10.1002/bies.202200150openalex-snapshot
Cell growth and the cell cycle: New insights about persistent questions
inferred← citeshttps://doi.org/10.1002/bies.202400048openalex-snapshot
Balancing Plk1 activity levels: The secret of synchrony between the cell and the centrosome cycle
inferred← citeshttps://doi.org/10.1002/btpr.70105openalex-snapshot
CRISPR ‐Cas9 lipid nanoparticles for targeting cyclin‐dependent kinases in the tumor microenvironment
inferred← citeshttps://doi.org/10.1002/cbic.202400426openalex-snapshot
A Dual Bispecific Hydrolysis Peptide‐Drug Conjugate Responsive to Micro‐Acidic and Reduction Circumstance Promotes Antitumor Efficacy in Triple‐Negative Breast Cancer
inferred← citeshttps://doi.org/10.1002/cpt.70490openalex-snapshot
Creatinine–Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib
inferred← citeshttps://doi.org/10.1002/gcc.23248openalex-snapshot
Related mechanisms, current treatments, and new perspectives in meningioma
inferred← citeshttps://doi.org/10.1002/jbt.70995openalex-snapshot
Downregulation of circ_0001112 Enhances Myocardial Infarction Through Regulation of miR‐324‐5p/CDK6 Axis
inferred← citeshttps://doi.org/10.1002/jcp.70113openalex-snapshot
ELF4/TRIB3/CDK6 Axis Promotes Cancer Stem Cell Activity in Endometrial Cancer
inferred← citeshttps://doi.org/10.1002/mba2.70012openalex-snapshot
Beyond Conventional Approaches: The Revolutionary Role of Nanoparticles in Breast Cancer
inferred← citeshttps://doi.org/10.1002/path.6084openalex-snapshot
Mutational landscape of primary spinal cord astrocytoma
inferred← citeshttps://doi.org/10.1002/slct.74289openalex-snapshot
Molecular Optimization of Benzimidazole Scaffolds for Targeted Protein Kinase Inhibition in Oncology
inferred← citeshttps://doi.org/10.1002/smll.202514464openalex-snapshot
Leveraging a Multienzymes‐Mimicking Nanozyme to Overcome CDK4/6 Inhibitor Resistance and Achieve Drug Repurposing in Oesophageal Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1002/tkm2.1441openalex-snapshot
Sasa veitchii extract exhibits antitumor effect against murine pancreatic adenocarcinoma in vivo and in vitro
inferred← citeshttps://doi.org/10.1007/978-3-031-33602-7_12openalex-snapshot
New Concepts in Cardio-Oncology
inferred← citeshttps://doi.org/10.1007/978-3-031-81813-4_27openalex-snapshot
Parathyroid Carcinoma
inferred← citeshttps://doi.org/10.1007/s00018-026-06132-1openalex-snapshot
The degradation revolution: harnessing targeted protein degradation for the treatment of human diseases
inferred← citeshttps://doi.org/10.1007/s00210-026-05618-wopenalex-snapshot
Rational design of pyrazole–oxime hybrids as dual-targeting agents for glioma and breast cancer brain metastasis
inferred← citeshttps://doi.org/10.1007/s00432-023-05560-xopenalex-snapshot
A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib
inferred← citeshttps://doi.org/10.1007/s10142-023-01253-3openalex-snapshot
CDK6 is a novel predictive and prognosis biomarker correlated with immune infiltrates in multiple human neoplasms, including small cell lung carcinoma
inferred← citeshttps://doi.org/10.1007/s10147-024-02625-wopenalex-snapshot
Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer
inferred← citeshttps://doi.org/10.1007/s10522-025-10271-6openalex-snapshot
Bibliometric insights into the cell cycle, aging, and metabolism: from molecular mechanisms to clinical implications
inferred← citeshttps://doi.org/10.1007/s10549-023-06866-7openalex-snapshot
A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1–CDK4 interaction
inferred← citeshttps://doi.org/10.1007/s11030-024-10939-0openalex-snapshot
Identification of the potential Pan-CDK antagonists: tracing the path of virtual screening and inhibitory activity on lung cancer cells
inferred← citeshttps://doi.org/10.1007/s11030-026-11603-5openalex-snapshot
Pyrimidine derivatives as anticancer agents targeting kinases: design strategies, biological evaluation, and structure–activity relationship insights
inferred← citeshttps://doi.org/10.1007/s11033-025-10531-1openalex-snapshot
Genetic alterations of Cyclin D-CDK4/6-INK4-RB pathway in prostate cancer
inferred← citeshttps://doi.org/10.1007/s11427-024-3015-1openalex-snapshot
Metformin sensitizes non-small cell lung cancer to CDK4/6 inhibitor treatment by reducing lysosomal trapping
inferred← citeshttps://doi.org/10.1007/s11684-024-1103-5openalex-snapshot
TRIM4 modulates the ubiquitin-mediated degradation of hnRNPDL and weakens sensitivity to CDK4/6 inhibitor in ovarian cancer
inferred← citeshttps://doi.org/10.1007/s12010-023-04829-8openalex-snapshot
Erianin Impedes the Proliferation and Metastatic Migration Through Suppression of STAT-3 Phosphorylation in Human Esophageal Cancer Cells
inferred← citeshttps://doi.org/10.1007/s12032-024-02385-7openalex-snapshot
Common skin cancers and their association with other non-cutaneous primary malignancies: a review of the literature
inferred← citeshttps://doi.org/10.1007/s12094-024-03666-3openalex-snapshot
Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib
inferred← citeshttps://doi.org/10.1007/s12282-024-01653-8openalex-snapshot
The role of C1orf50 in breast cancer progression and prognosis
inferred← citeshttps://doi.org/10.1007/s12609-022-00461-3openalex-snapshot
Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling
inferred← citeshttps://doi.org/10.1007/s13402-025-01125-xopenalex-snapshot
TFE3 fusion proteins promoted the progression of Xp11.2 translocation renal cell carcinoma through post-translational modification of PDL1 by upregulating CCND1/Cyclin D1
inferred← citeshttps://doi.org/10.1007/s42250-025-01224-0openalex-snapshot
TiO2 Nanoparticles Catalyzed Synthesis, Pharmacological Evaluation, and Molecular Docking Studies of New Pyrido[2,3-d]Pyrimidine Derivatives as CDK1 Inhibitors
inferred← citeshttps://doi.org/10.1007/s44178-024-00090-zopenalex-snapshot
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of mucosal melanoma
inferred← citeshttps://doi.org/10.1007/s44178-024-00100-0openalex-snapshot
The role of targeting CDK4/6 in cancer immunotherapy
inferred← citeshttps://doi.org/10.1007/s44371-025-00405-7openalex-snapshot
In silico identification of CDK1 as a candidate target in breast cancer via integrative transcriptomic and docking analysis of Moringa Oleifera compounds
inferred← citeshttps://doi.org/10.1007/s44371-026-00780-9openalex-snapshot
Cyano containing scaffolds in cancer drug discovery from medicinal chemistry insights to therapeutic efficiency
inferred← citeshttps://doi.org/10.1016/b978-0-443-21816-3.00002-6openalex-snapshot
Degraders of cell cycle- and antiapoptosis-related proteins
inferred← citeshttps://doi.org/10.1016/b978-0-443-23932-8.00022-4openalex-snapshot
Palbociclib, ribociclib, and abemaciclib: potent and selective CDK4/6 inhibitors for the treatment of breast cancer
inferred← citeshttps://doi.org/10.1016/b978-0-443-33565-5.00013-xopenalex-snapshot
Managing big data for TNBC research
inferred← citeshttps://doi.org/10.1016/b978-0-443-44185-1.00011-2openalex-snapshot
Introduction to cancer
inferred← citeshttps://doi.org/10.1016/b978-0-443-44611-5.00010-9openalex-snapshot
Cytotoxic profile, molecular modeling, cell cycle arrest, and apoptosis induced by CDK4/6 inhibitors
inferred← citeshttps://doi.org/10.1016/b978-0-443-44611-5.00011-0openalex-snapshot
Resistance and resistance markers of CDK4/6 inhibitors
inferred← citeshttps://doi.org/10.1016/bs.apcsb.2022.11.008openalex-snapshot
CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells
inferred← citeshttps://doi.org/10.1016/bs.apcsb.2023.02.003openalex-snapshot
Therapeutic targets in cancer treatment: Cell cycle proteins
inferred← citeshttps://doi.org/10.1016/bs.mcb.2023.02.018openalex-snapshot
Flow cytometry-assisted quantification of cell cycle arrest in cancer cells treated with CDK4/6 inhibitors
inferred← citeshttps://doi.org/10.1016/j.acra.2024.06.006openalex-snapshot
MR-Based Radiomics Predicts CDK6 Expression and Prognostic Value in High-grade Glioma
inferred← citeshttps://doi.org/10.1016/j.actbio.2026.09.012openalex-snapshot
Microneedle patch integrated with hydroxyapatite nanoparticles and abemaciclib for treatment of meningioma
inferred← citeshttps://doi.org/10.1016/j.antiviral.2023.105720openalex-snapshot
Breaking the mold: Overcoming resistance to immune checkpoint inhibitors
inferred← citeshttps://doi.org/10.1016/j.apsb.2026.03.050openalex-snapshot
Advanced drug delivery platforms targeting cellular senescence: A promising strategy for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.arcmed.2026.103383openalex-snapshot
Pro-Tumorigenic Roles of Cyclin Dependent Kinase 2 and its Associated Cyclins in Cholangiocarcinoma Progression under High Glucose Condition
inferred← citeshttps://doi.org/10.1016/j.bbcan.2023.188912openalex-snapshot
Immunomodulatory effects of CDK4/6 inhibitors
inferred← citeshttps://doi.org/10.1016/j.bbrc.2023.09.032openalex-snapshot
Doxorubicin-induced senescence promotes resistance to cell death by modulating genes associated with apoptotic and necrotic pathways in prostate cancer DU145 CD133+/CD44+ cells
inferred← citeshttps://doi.org/10.1016/j.bbrc.2024.149808openalex-snapshot
Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma
inferred← citeshttps://doi.org/10.1016/j.bbrc.2026.154458openalex-snapshot
A nuclear-targeted PROTAC enables subcellular-selective degradation of AURKA
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107285openalex-snapshot
Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.108080openalex-snapshot
Discovery of a novel CDK4/6 and HDAC dual-targeting agent for the treatment of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.109893openalex-snapshot
Design, synthesis and anti-bladder cancer activity of novel dihydroartemisinin-ibuprofen hybrids
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.110344openalex-snapshot
Prenylated 4-Hydroxycoumarin derivatives as inducers of CDK4/6-mediated cell cycle arrest: From design and synthesis to in vitro and in vivo evaluation of their anti-breast Cancer activity
inferred← citeshttps://doi.org/10.1016/j.bioorg.2026.110565openalex-snapshot
CDK4/6-related inhibitors from a medicinal chemistry perspective: Research advances in the past six years (2020–2025)
inferred← citeshttps://doi.org/10.1016/j.bios.2025.117784openalex-snapshot
Self-calibrated SERS-LFIA biosensor based on AgNF for in-site and rapid detection of protein kinase biomarker PEAK1
inferred← citeshttps://doi.org/10.1016/j.biosystems.2026.105929openalex-snapshot
Stress-driven strategic games in cancer
inferred← citeshttps://doi.org/10.1016/j.bmc.2025.118109openalex-snapshot
Thienopyrimidine: A promising scaffold in the development of kinase inhibitors with anticancer activities
inferred← citeshttps://doi.org/10.1016/j.bmc.2025.118535openalex-snapshot
New pyrazolo[1,5-a]pyrimidine derivatives as potential CDK2 inhibitors and apoptosis-driven antiproliferative agents
inferred← citeshttps://doi.org/10.1016/j.bmcl.2024.129769openalex-snapshot
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
inferred← citeshttps://doi.org/10.1016/j.breast.2022.10.018openalex-snapshot
Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer
inferred← citeshttps://doi.org/10.1016/j.breast.2025.104527openalex-snapshot
BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study
inferred← citeshttps://doi.org/10.1016/j.breast.2026.104791openalex-snapshot
WITHDRAWN: From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2– breast cancer
inferred← citeshttps://doi.org/10.1016/j.canlet.2023.216181openalex-snapshot
A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency
inferred← citeshttps://doi.org/10.1016/j.canlet.2024.216747openalex-snapshot
CD63+ cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20
inferred← citeshttps://doi.org/10.1016/j.canlet.2024.216956openalex-snapshot
Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.canlet.2026.218349openalex-snapshot
Targeting PCK1 to overcome CDK4/6 inhibitor resistance for breast cancer therapy
inferred← citeshttps://doi.org/10.1016/j.canlet.2026.218359openalex-snapshot
Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology
inferred← citeshttps://doi.org/10.1016/j.ccell.2024.09.009openalex-snapshot
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
inferred← citeshttps://doi.org/10.1016/j.ccell.2025.02.006openalex-snapshot
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
inferred← citeshttps://doi.org/10.1016/j.ccell.2025.02.007openalex-snapshot
A CDK4-selective inhibitor puts the brakes on cancer cells
inferred← citeshttps://doi.org/10.1016/j.cclet.2026.112601openalex-snapshot
Biomimetic nanomedicine targeted epigenetic regulation sensitizes orthotopic bladder cancer therapy
inferred← citeshttps://doi.org/10.1016/j.cej.2025.160172openalex-snapshot
Microfluidic fabrication of lipid nanoparticles for co-delivery of siRNA and hydroxychloroquine: An engineered theranostic platform for enhanced breast cancer treatment
inferred← citeshttps://doi.org/10.1016/j.cell.2023.05.013openalex-snapshot
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity
inferred← citeshttps://doi.org/10.1016/j.cellsig.2024.111562openalex-snapshot
CTSG restraines the proliferation and metastasis of head and neck squamous cell carcinoma by blocking the JAK2/STAT3 pathway
inferred← citeshttps://doi.org/10.1016/j.cellsig.2025.112051openalex-snapshot
Combination of Cbl-b inhibitor NX-1607 and CDK4/6 inhibitor abemaciclib enhances anti-tumor immunity through PLCγ1/ERK-mediated T cell activation
inferred← citeshttps://doi.org/10.1016/j.cellsig.2025.112296openalex-snapshot
Selenium-binding protein 1 suppresses cell cycle progression via cyclin-dependent kinase 2 breakdown in colon carcinoma
inferred← citeshttps://doi.org/10.1016/j.celrep.2023.112768openalex-snapshot
Cyclin E/CDK2 and feedback from soluble histone protein regulate the S phase burst of histone biosynthesis
inferred← citeshttps://doi.org/10.1016/j.celrep.2023.113198openalex-snapshot
Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer
inferred← citeshttps://doi.org/10.1016/j.celrep.2025.116769openalex-snapshot
p57 increases immunotherapy efficacy by promoting cGAS-STING-mediated innate sensing in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2024.104405openalex-snapshot
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2026.105427openalex-snapshot
The evolving landscape of CDK2 inhibition in cancer: Therapeutic potential, clinical progress, and future directions
inferred← citeshttps://doi.org/10.1016/j.ctrv.2025.102924openalex-snapshot
Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2026.103224openalex-snapshot
Targeted protein degradation as next-generation therapeutic modality for childhood cancer
inferred← citeshttps://doi.org/10.1016/j.drudis.2025.104407openalex-snapshot
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance
inferred← citeshttps://doi.org/10.1016/j.drup.2024.101103openalex-snapshot
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
inferred← citeshttps://doi.org/10.1016/j.ejcb.2023.151318openalex-snapshot
Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116547openalex-snapshot
Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.117264openalex-snapshot
Novel technetium-99m-labelled ribociclib isocyanide derivatives for imaging cyclin-dependent kinase 4/6 (CDK4/6) expression in cancer
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.117503openalex-snapshot
Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.118400openalex-snapshot
Advances in radiolabelled CDK4/6 inhibitors for in vivo imaging of CDK4/6 activity in tumours
inferred← citeshttps://doi.org/10.1016/j.envint.2026.110327openalex-snapshot
Integrative network toxicology and multi-omics analyses reveal divergent molecular programs underlying pyrethroid-induced ovarian dysfunction
inferred← citeshttps://doi.org/10.1016/j.esmoop.2025.105913openalex-snapshot
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer
inferred← citeshttps://doi.org/10.1016/j.fsi.2025.110530openalex-snapshot
Inhibition of opioid growth factor receptor (OGFR) promotes wound healing in the freshwater pearl mussel (Hyriopsis schlegelii)
inferred← citeshttps://doi.org/10.1016/j.gendis.2025.101732openalex-snapshot
Integrative high-throughput studies to develop novel targets and drugs for the treatment of advanced prostate cancer
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e29933openalex-snapshot
FAM83B promotes cell proliferation via regulating the expression of CDK4/CDK6/CCND1 complex in laryngeal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2022.07.156openalex-snapshot
Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.113059openalex-snapshot
Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2− breast cancer
inferred← citeshttps://doi.org/10.1016/j.isci.2025.113304openalex-snapshot
Optochemical control of G1 cell cycle by regulating CDK4/6 degradation
inferred← citeshttps://doi.org/10.1016/j.jare.2023.05.002openalex-snapshot
Modulating autophagy to treat diseases: A revisited review on in silico methods
inferred← citeshttps://doi.org/10.1016/j.jbc.2022.102692openalex-snapshot
Loss of transcription factor EB dysregulates the G1/S transition and DNA replication in mammary epithelial cells
inferred← citeshttps://doi.org/10.1016/j.jbc.2023.105330openalex-snapshot
Growing and dividing: how O-GlcNAcylation leads the way
inferred← citeshttps://doi.org/10.1016/j.jff.2024.106498openalex-snapshot
Cowpea bean β-vignin-derived AQQSY peptide exerts an anticancer effect by inducing cell cycle arrest in the G0/G1 phase and modulating apoptotic signals
inferred← citeshttps://doi.org/10.1016/j.jmb.2025.168952openalex-snapshot
Differences in Binding Affinity Among Cell-cycle CDK and Cyclin Pairs
inferred← citeshttps://doi.org/10.1016/j.jmb.2025.169121openalex-snapshot
Distinct Allosteric Networks in CDK4 and CDK6 in the Cell Cycle and in Drug Resistance
inferred← citeshttps://doi.org/10.1016/j.jmgm.2026.109591openalex-snapshot
Structure-based drug repurposing for CDK6: Molecular docking and molecular dynamics characterization of FDA-approved non-oncological compounds
inferred← citeshttps://doi.org/10.1016/j.jpet.2025.103726openalex-snapshot
Inhibition of cyclin-dependent kinase 4/6 attenuates airway remodeling in a murine severe asthma model by suppressing group 2 innate lymphoid cells proliferation
inferred← citeshttps://doi.org/10.1016/j.jprot.2025.105566openalex-snapshot
The dynamics of ubiquitination and its role within the proteome of extracellular vesicles
inferred← citeshttps://doi.org/10.1016/j.lddd.2025.100164openalex-snapshot
Uncovering celecoxib’s anti-breast cancer mechanisms through network pharmacology, molecular docking, and dynamics
inferred← citeshttps://doi.org/10.1016/j.lfs.2024.122635openalex-snapshot
Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety
inferred← citeshttps://doi.org/10.1016/j.molcel.2023.10.016openalex-snapshot
CDK4/6 inhibitor-mediated cell overgrowth triggers osmotic and replication stress to promote senescence
inferred← citeshttps://doi.org/10.1016/j.molcel.2023.10.020openalex-snapshot
Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest
inferred← citeshttps://doi.org/10.1016/j.molcel.2026.08.007openalex-snapshot
Cyclin E-CDK2 regulates cancer cell transcriptional program and response to immunotherapy through BRD4
inferred← citeshttps://doi.org/10.1016/j.mtbio.2026.103485openalex-snapshot
Morpho-crystallo-electronic Co-optimization of PtAu/GOx nanozyme for enhanced NIR-II photothermal-cascade catalytic tumor therapy
inferred← citeshttps://doi.org/10.1016/j.oor.2024.100469openalex-snapshot
Deciphering genomic complexity: Understanding intratumor heterogeneity, clonal evolution, and therapeutic vulnerabilities in oral squamous cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2024.108673openalex-snapshot
Mechanistic insights into medulloblastoma relapse
inferred← citeshttps://doi.org/10.1016/j.phrs.2025.107955openalex-snapshot
Advances in Cutaneous Melanoma Therapy: The Emerging Role of CDK4/6 Inhibitors
inferred← citeshttps://doi.org/10.1016/j.phymed.2024.155775openalex-snapshot
Hernandezine acts as a CDK4 suppressor inhibiting tumor growth by the CDK4/PKM2/NRF2 axis in colon cancer
inferred← citeshttps://doi.org/10.1016/j.phymed.2024.155804openalex-snapshot
Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer
inferred← citeshttps://doi.org/10.1016/j.redox.2023.102931openalex-snapshot
The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance
inferred← citeshttps://doi.org/10.1016/j.saa.2026.127609openalex-snapshot
Novel active site -targeted fluorescent probes for real-time monitoring of CDK4/6 in tumor cells and tissues
inferred← citeshttps://doi.org/10.1016/j.semcancer.2023.12.002openalex-snapshot
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer
inferred← citeshttps://doi.org/10.1016/j.snb.2022.133157openalex-snapshot
Construction of broom-like Ag@N,O-C sensing interface for electrochemical detection of circulating tumor DNA using entropy-driven DNA walker
inferred← citeshttps://doi.org/10.1016/j.str.2024.04.012openalex-snapshot
Slower CDK4 and faster CDK2 activation in the cell cycle
inferred← citeshttps://doi.org/10.1016/j.taap.2025.117333openalex-snapshot
CB-5083 and luteolin synergistically induce the apoptosis of bladder cancer cells via multiple mechanisms
inferred← citeshttps://doi.org/10.1016/j.taap.2025.117530openalex-snapshot
Cell morphology and gene expression: tracking changes and complementarity across time and cell lines
inferred← citeshttps://doi.org/10.1016/j.taap.2025.117690openalex-snapshot
Celastrol delays the progression of hepatocellular carcinoma by suppressing SLC1A5-mediated glutamine dependence
inferred← citeshttps://doi.org/10.1016/j.tchem.2026.100156openalex-snapshot
1,2,5-Thiadiazocan-7-one 1,1-dioxides — a novel charted region in the chemical space of 8-membered azasultams
inferred← citeshttps://doi.org/10.1016/j.tibs.2025.12.007openalex-snapshot
Diversity in CDK structural mechanisms of regulation and drug discovery opportunities
inferred← citeshttps://doi.org/10.1016/j.tiv.2025.106054openalex-snapshot
Environmentally relevant concentrations of antimony pose potential risks to human health: An evaluation on human umbilical vein endothelial cells
inferred← citeshttps://doi.org/10.1016/j.tiv.2026.106293openalex-snapshot
Polyethylene glycol encapsulation enhances phytol-induced oxidative stress, mitochondrial dysfunction and apoptotic death in oral carcinoma cells
inferred← citeshttps://doi.org/10.1016/j.tranon.2024.102212openalex-snapshot
BET inhibitor and CDK4/6 inhibitor synergistically inhibit breast cancer by suppressing BRD4 stability and DNA damage repair
inferred← citeshttps://doi.org/10.1016/j.trecan.2026.03.004openalex-snapshot
Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies
inferred← citeshttps://doi.org/10.1016/j.trsl.2024.06.004openalex-snapshot
IGF2BP3/NCBP1 complex inhibits renal tubular senescence through regulation of CDK6 mRNA stability
inferred← citeshttps://doi.org/10.1016/j.yexcr.2025.114697openalex-snapshot
Upregulation of Linc00960 promotes colorectal cancer cell proliferation by regulating hsa-miR-107/CDK6 axis
inferred← citeshttps://doi.org/10.1016/j.ymthe.2024.08.001openalex-snapshot
Small-molecule-based targeted therapy in liver cancer
inferred← citeshttps://doi.org/10.1016/s0091-679x(24)00009-8openalex-snapshot
Cellular senescence and aging at the crossroad between immunity and cancer
inferred← citeshttps://doi.org/10.1016/s1875-5364(23)60420-0openalex-snapshot
Maackiain inhibits proliferation and promotes apoptosis of nasopharyngeal carcinoma cells by inhibiting the MAPK/Ras signaling pathway
inferred← citeshttps://doi.org/10.1016/s1875-5364(25)60846-6openalex-snapshot
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
inferred← citeshttps://doi.org/10.1021/acs.est.5c10762openalex-snapshot
Azocyclotin Binds CDK4 to Disrupt DNA Methylation in Zebrafish Epigenetic Transgenerational Inheritance
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01648openalex-snapshot
Targeted Protein Degradation Induced by HEMTACs Based on HSP90
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c00516openalex-snapshot
Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1β Secretion and T Cell Adjuvanticity
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c00965openalex-snapshot
Development of Degraders of Cyclin-Dependent Kinases 4 and 6 Based on Rational Drug Design
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c01323openalex-snapshot
Bipyridine Derivatives as NOP2/Sun RNA Methyltransferase 3 Inhibitors for the Treatment of Colorectal Cancer
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c01686openalex-snapshot
Elucidating Binding Selectivity in Cyclin-Dependent Kinases 4, 6, and 9: Development of Highly Potent and Selective CDK4/9 Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c02080openalex-snapshot
Discovery of Potent and Selective CDK4/6 Inhibitors for the Treatment of Chemotherapy-Induced Myelosuppression
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c02441openalex-snapshot
Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability
inferred← citeshttps://doi.org/10.1021/acs.jpcb.4c03243openalex-snapshot
Binding Modalities and Phase-Specific Regulation of Cyclin/Cyclin-Dependent Kinase Complexes in the Cell Cycle
inferred← citeshttps://doi.org/10.1021/acs.jpcb.4c06497openalex-snapshot
Rationalize the Functional Roles of Protein–Protein Interactions in Targeted Protein Degradation by Kinetic Monte Carlo Simulations
inferred← citeshttps://doi.org/10.1021/acs.jproteome.2c00203openalex-snapshot
Subgroup-Enriched Pathways and Kinase Signatures in Medulloblastoma Patient-Derived Xenografts
inferred← citeshttps://doi.org/10.1021/acsnano.3c10142openalex-snapshot
Targeted Liposomes Sensitize Plastic Melanoma to Ferroptosis via Senescence Induction and Coenzyme Depletion
inferred← citeshttps://doi.org/10.1021/acsnano.5c18165openalex-snapshot
Senescence-Primed Ferroptosis Enabled by a Metal–Organic Framework Nanoplatform for Enhanced Cancer Therapy
inferred← citeshttps://doi.org/10.1021/acsomega.4c09472openalex-snapshot
Physiologically Based Pharmacokinetic Model of Plasma and Intracranial Pharmacokinetics and CDK4/6 Occupancy of Abemaciclib to Optimizing Dosing Regimen for Brain Metastatic Patients
inferred← citeshttps://doi.org/10.1021/acsptsci.6c00005openalex-snapshot
Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance
inferred← citeshttps://doi.org/10.1021/jacs.5c04918openalex-snapshot
DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1–CDK4/6 Complex Protein Degradation
inferred← citeshttps://doi.org/10.1021/jacsau.5c00223openalex-snapshot
Near-Infrared-Activated Photocages Made to Order: Late-Stage Caging Protocol
inferred← citeshttps://doi.org/10.1038/s12276-025-01395-3openalex-snapshot
Targeting CDK4/6 in breast cancer
inferred← citeshttps://doi.org/10.1038/s41388-024-02987-5openalex-snapshot
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer
inferred← citeshttps://doi.org/10.1038/s41388-025-03378-0openalex-snapshot
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
inferred← citeshttps://doi.org/10.1038/s41389-023-00475-1openalex-snapshot
CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer
inferred← citeshttps://doi.org/10.1038/s41392-024-01823-2openalex-snapshot
Tumor biomarkers for diagnosis, prognosis and targeted therapy
inferred← citeshttps://doi.org/10.1038/s41392-024-02080-zopenalex-snapshot
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
inferred← citeshttps://doi.org/10.1038/s41417-024-00747-xopenalex-snapshot
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
inferred← citeshttps://doi.org/10.1038/s41417-024-00862-9openalex-snapshot
LRP11-AS1 mediates enterotoxigenic Bacteroides fragilis-related carcinogenesis in colorectal Cancer via the miR-149-3p/CDK4 pathway
inferred← citeshttps://doi.org/10.1038/s41417-026-01014-xopenalex-snapshot
HAUS1-mediated activation of CDK4 transcription enhances proliferation, invasion and migration in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1038/s41418-023-01196-zopenalex-snapshot
Cyclers’ kinases in cell division: from molecules to cancer therapy
inferred← citeshttps://doi.org/10.1038/s41418-025-01634-0openalex-snapshot
Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibition
inferred← citeshttps://doi.org/10.1038/s41419-024-06949-3openalex-snapshot
Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer
inferred← citeshttps://doi.org/10.1038/s41419-024-06967-1openalex-snapshot
Potential of GSPT1 as a novel target for glioblastoma therapy
inferred← citeshttps://doi.org/10.1038/s41420-024-02218-6openalex-snapshot
CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response
inferred← citeshttps://doi.org/10.1038/s41420-025-02292-4openalex-snapshot
CDK14 regulates the development and repair of lung
inferred← citeshttps://doi.org/10.1038/s41420-025-02565-yopenalex-snapshot
Circular RNA circLIMK1-005 promotes the progression of lung adenocarcinoma by interacting with RPA1 protein to activate CDK4 signaling
inferred← citeshttps://doi.org/10.1038/s41467-023-37593-8openalex-snapshot
Mapping the landscape of genetic dependencies in chordoma
inferred← citeshttps://doi.org/10.1038/s41467-023-39854-yopenalex-snapshot
The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer
inferred← citeshttps://doi.org/10.1038/s41467-023-43716-yopenalex-snapshot
Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity
inferred← citeshttps://doi.org/10.1038/s41467-024-49875-wopenalex-snapshot
O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer
inferred← citeshttps://doi.org/10.1038/s41467-024-55605-zopenalex-snapshot
CDK4 inactivation inhibits apoptosis via mitochondria-ER contact remodeling in triple-negative breast cancer
inferred← citeshttps://doi.org/10.1038/s41467-025-55904-zopenalex-snapshot
Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer
inferred← citeshttps://doi.org/10.1038/s41467-025-57293-9openalex-snapshot
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
inferred← citeshttps://doi.org/10.1038/s41467-025-63669-8openalex-snapshot
Temporal control of human DNA replication licensing by CDK4/6-RB signalling and chemical genetics
showing the first 200 of 469 · page through all 469
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.